CPMC-R.K. DAVIES MEDICAL CENTER
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 050008
- Received
- $1,865,721 in 79 records, 2024 ($1,127,132 general, $738,589 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 7 | $1,127,132 |
| 2024 | Research payment | 72 | $738,589 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Lilly USA, LLC | 3 | $1,115,920 | 2024 |
| Abbott Laboratories | 12 | $220,897 | 2024 |
| ABBVIE INC. | 9 | $144,758 | 2024 |
| Genentech, Inc. | 7 | $143,199 | 2024 |
| Biogen, Inc. | 2 | $84,575 | 2024 |
| Eli Lilly and Company | 5 | $50,246 | 2024 |
| Gilead Sciences, Inc. | 7 | $46,050 | 2024 |
| GENZYME CORPORATION | 4 | $35,584 | 2024 |
| AtriCure, Inc. | 5 | $8,242 | 2024 |
| Jenavalve Technology, Inc. | 1 | $6,712 | 2024 |
| Siemens Medical Solutions USA, Inc. | 2 | $4,000 | 2024 |
| Immunocore Limited | 4 | $1,458 | 2024 |
| CSL Behring | 2 | $1,165 | 2024 |
| ARGENX US, INC. | 13 | $944 | 2024 |
| Novocure Inc. | 1 | $814 | 2024 |
| UCB SA | 1 | $652 | 2024 |
| Tandem Diabetes Care, Inc. | 1 | $500 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Grant | 5 | $1,119,920 |
| Research payment | 72 | $738,589 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $7,212 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-30 | ABBVIE INC. | $5,821 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-12-27 | Abbott Laboratories | $30,250 | Research payment | Cash or cash equivalent | FreeStyle Libre 2 Device, DIABETES CARE | A PILOT STUDY COMPARING LIFESTYLE INTERVENTIONS AND INTERMITTENT CONTINUOUS GLUCOSE MONITORING IN PR | 2024 |
| 2024-12-20 | Genentech, Inc. | $22,661 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-12-19 | Immunocore Limited | $364 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators | 2024 |
| 2024-12-05 | ABBVIE INC. | $23,765 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-12-05 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-11-21 | Eli Lilly and Company | $2,603 | Research payment | In-kind items and services | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2024 | |
| 2024-11-18 | Abbott Laboratories | $101,157 | Research payment | Cash or cash equivalent | AGILIS Device, ELECTROPHYSIOLOGY | VOLT-AF IDE Clinical Study | 2024 |
| 2024-11-13 | Gilead Sciences, Inc. | $3,614 | Research payment | Cash or cash equivalent | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2024 | |
| 2024-11-13 | Gilead Sciences, Inc. | $1,530 | Research payment | Cash or cash equivalent | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2024 | |
| 2024-11-12 | Abbott Laboratories | $2,023 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Assessing the Glycemic Impact of an Online Lifestyle Intervention using CGM (Continuous Glucose Monitoring) | 2024 |
| 2024-11-11 | Abbott Laboratories | $4,423 | Research payment | Cash or cash equivalent | TRICLIP Device, STRUCTURAL HEART | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal | 2024 |
| 2024-11-08 | Genentech, Inc. | $1,694 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-11-08 | Eli Lilly and Company | $9 | Research payment | In-kind items and services | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC | 2024 | |
| 2024-11-07 | ABBVIE INC. | $5,665 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compar | 2024 | |
| 2024-11-04 | Genentech, Inc. | $10,266 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-11-01 | Gilead Sciences, Inc. | $6,297 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2024 |
| 2024-11-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-10-23 | Abbott Laboratories | $3,420 | Research payment | In-kind items and services | FreeStyle Libre 3 Device, DIABETES CARE | Assessing the Glycemic Impact of an Online Lifestyle Intervention using CGM (Continuous Glucose Monitoring) | 2024 |
| 2024-10-16 | Lilly USA, LLC | $600,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-10-16 | Lilly USA, LLC | $31,632 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-10-03 | ABBVIE INC. | $12,771 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-10-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-09-19 | Immunocore Limited | $364 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators | 2024 |
| 2024-09-16 | GENZYME CORPORATION | $22,060 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 | |
| 2024-09-06 | Gilead Sciences, Inc. | $15,133 | Research payment | Cash or cash equivalent | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2024 | |
| 2024-09-04 | ABBVIE INC. | $22,011 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-09-04 | ABBVIE INC. | $17,267 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2024 | |
| 2024-09-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-08-26 | Lilly USA, LLC | $484,288 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-08-21 | Siemens Medical Solutions USA, Inc. | $1,500 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-08-14 | Abbott Laboratories | $7,078 | Research payment | Cash or cash equivalent | TRICLIP Device, STRUCTURAL HEART | Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN PAtients Treated with the Tricuspid ValvE Repair System Pivotal | 2024 |
| 2024-08-07 | Abbott Laboratories | $51,246 | Research payment | Cash or cash equivalent | AGILIS Device, ELECTROPHYSIOLOGY | VOLT-AF IDE | 2024 |
| 2024-08-02 | ABBVIE INC. | $7,227 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-08-01 | Gilead Sciences, Inc. | $13,612 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2024 |
| 2024-08-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-07-18 | Genentech, Inc. | $46,484 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-07-05 | ABBVIE INC. | $32,961 | Research payment | Cash or cash equivalent | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-C | 2024 | |
| 2024-07-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-07-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-06-13 | Immunocore Limited | $364 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators | 2024 |
| 2024-06-12 | Jenavalve Technology, Inc. | $6,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments) | Cash or cash equivalent | 2024 | ||
| 2024-06-07 | Gilead Sciences, Inc. | $2,560 | Research payment | Cash or cash equivalent | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2024 | |
| 2024-05-21 | Gilead Sciences, Inc. | $3,301 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cho | 2024 |
| 2024-05-08 | Abbott Laboratories | $7,015 | Research payment | Cash or cash equivalent | TRICLIP Device, STRUCTURAL HEART | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal | 2024 |
| 2024-05-01 | Siemens Medical Solutions USA, Inc. | $2,500 | Grant | Cash or cash equivalent | Varian Ethos Treatment Planning Device, Oncology | 2024 | |
| 2024-05-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-04-30 | AtriCure, Inc. | $2,392 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR | 2024 |
| 2024-04-18 | Genentech, Inc. | $10,224 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-04-16 | Abbott Laboratories | $10,000 | Research payment | Cash or cash equivalent | AGILIS Device, ELECTROPHYSIOLOGY | VOLT-AF IDE Clinical Study | 2024 |
| 2024-04-12 | Abbott Laboratories | $50 | Research payment | In-kind items and services | AGILIS Device, ELECTROPHYSIOLOGY | VOLT-AF IDE Clinical Study | 2024 |
| 2024-04-12 | Abbott Laboratories | $15 | Research payment | In-kind items and services | AGILIS Device, ELECTROPHYSIOLOGY | VOLT-AF IDE Clinical Study | 2024 |
| 2024-04-10 | Eli Lilly and Company | $24,178 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC | 2024 | |
| 2024-04-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-03-12 | Eli Lilly and Company | $22,581 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 | |
| 2024-03-07 | ABBVIE INC. | $17,267 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with | 2024 | |
| 2024-03-06 | AtriCure, Inc. | $850 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR | 2024 |
| 2024-03-06 | AtriCure, Inc. | $500 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR | 2024 |
| 2024-03-06 | AtriCure, Inc. | $500 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | PIVOTAL STUDY OF A DUAL EPICARDIAL AND ENDOCARDIAL PROCEDURE DEEP APPROACH FOR TREATMENT OF SUBJECTS WITH PERSISTENT OR | 2024 |
| 2024-03-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-02-26 | GENZYME CORPORATION | $6,504 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2024 | |
| 2024-02-14 | CSL Behring | $72 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2024 | |
| 2024-02-13 | CSL Behring | $1,093 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2024 | |
| 2024-02-12 | Abbott Laboratories | $4,219 | Research payment | Cash or cash equivalent | TRICLIP Device, STRUCTURAL HEART | Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal | 2024 |
| 2024-02-01 | Novocure Inc. | $814 | Research payment | Cash or cash equivalent | EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi | 2024 | |
| 2024-02-01 | ARGENX US, INC. | $104 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-02-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
| 2024-01-29 | Immunocore Limited | $364 | Research payment | Cash or cash equivalent | KIMMTRAK Drug, Oncology | A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators | 2024 |
| 2024-01-22 | GENZYME CORPORATION | $6,625 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2024 | |
| 2024-01-18 | Genentech, Inc. | $6,552 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-01-16 | UCB SA | $652 | Research payment | Cash or cash equivalent | Zilbrysq Biological, Neurology | Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis | 2024 |
| 2024-01-11 | Genentech, Inc. | $45,318 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2024 |
| 2024-01-09 | Eli Lilly and Company | $874 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 | |
| 2024-01-05 | Biogen, Inc. | $20,264 | Research payment | Cash or cash equivalent | QALSODY Drug, Neurology | A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismuta | 2024 |
| 2024-01-04 | AtriCure, Inc. | $4,000 | Research payment | Cash or cash equivalent | ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Device, CARDIOVASCULAR | ATRICURE INCORAF RETRO | 2024 |
| 2024-01-03 | Biogen, Inc. | $64,311 | Research payment | Cash or cash equivalent | ADUHELM Biological, Neurology | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Bene | 2024 |
| 2024-01-03 | GENZYME CORPORATION | $395 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443 | 2024 | |
| 2024-01-01 | ARGENX US, INC. | $70 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments